AstraZeneca Partners With Oracle on AI-Driven Clinical Research

3-line summary

• AstraZeneca and Oracle announced a partnership to use AI to improve clinical research processes, drawing on Oracle's AI, cloud computing, and data-management systems; the collaboration focuses on applying AI to connect scientific research with clinical workflows rather than discovering new drug targets.
• Planned applications include clinical-trial patient recruitment, earlier disease diagnosis, and drug-safety monitoring; the first program will address hypertension treatment and clinical research in Abu Dhabi alongside healthcare group M42, before expanding to additional projects across the US, Middle East, and Europe.
• The partnership is expected to span AstraZeneca's core therapeutic areas, including oncology, cardiovascular disease, kidney and metabolic disease, respiratory and immunology, and rare diseases; neither company disclosed financial terms or a contract duration.

This summary is our own processing of the source article; see the source link below for full context.